By Yasin Ebrahim
Investing.com – Wall Street gave back gains on Tuesday after data showed that Gilead Sciences’ antiviral medicine remdesivir failed to speed the improvement of patients with Covid-19.
“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said WHO spokesperson Tarik Jasarevic.
The Dow was up 1.3%, or 241 points, but had been up more than 350 points earlier.
But Gilead said the data suggest a "potential benefit," according to STAT News, which saw the document.
Shares of Gilead (NASDAQ:GILD) fell 3.8%.